Risk Management plan Indehaveren af markedsføringstilladelsen forpligter sig til at udføre studier og yderligere pharmacovigilanceaktiviteter, som beskrevet i Pharmacovigilanceplanen, version 3. 0 af Risk Management Planen (RMP), som beskrevet i modul 1. 8. 2 i markedsføringstilladelsen og enhver senere opdatering af RMP, som er godkendt af CHMP.
Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 3.0 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP.